sana biotechnology is focused on utilizing engineered cells as medicines for patients. the ability to modify genes and use cells as medicines will be one of the most important advances in healthcare over the next several decades. sana is building differentiated capabilities across the spectrum of cell and gene therapy. three aspirations drive sana as we look to discover treatments for patients with poor outcomes or currently untreatable diseases. the first is the ability to repair and control the genes in any cell in the body. we are advancing novel delivery technologies with the goal of being able to deliver any payload to any cell in a specific, predictable, and repeatable manner, paving the way for next-generation in vivo gene therapy. next is the ability to differentiate pluripotent stem cells ex vivo into immune-cloaked functional cells with the aspiration of being able to replace any missing or damaged cells in the body. last is a belief we can enable broader access to ou
Company profile
Ticker
SANA
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Cobalt Biomedicine, Inc. • Oscine Corp. • Cytocardia, Inc. ...
SANA stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
18 Apr 24
S-3ASR
Automatic shelf registration
1 Mar 24
8-K
Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
29 Feb 24
8-K
Sana Biotechnology Announces Pricing of Upsized Public Offering
8 Feb 24
424B5
Prospectus supplement for primary offering
8 Feb 24
FWP
Free writing prospectus
7 Feb 24
424B5
Prospectus supplement for primary offering
7 Feb 24
8-K
Results of Operations and Financial Condition
7 Feb 24
8-K
Regulation FD Disclosure
9 Jan 24
8-K
Regulation FD Disclosure
11 Dec 23
Latest ownership filings
4
Hans Edgar Bishop
8 Apr 24
3
Initial statement of insider ownership
8 Apr 24
SC 13G/A
FMR LLC
3 Apr 24
4
Patrick Y Yang
11 Mar 24
4
DOUGLAS E WILLIAMS
8 Mar 24
4
Steve Harr
8 Mar 24
4
Christian Hordo
8 Mar 24
4
Nathan Hardy
8 Mar 24
4
Bernard J Cassidy
8 Mar 24
SC 13G/A
BAILLIE GIFFORD & CO
7 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 172.28 mm | 172.28 mm | 172.28 mm | 172.28 mm | 172.28 mm | 172.28 mm |
Cash burn (monthly) | 4.01 mm | 130.92 k | 727.00 k | 23.69 mm | 21.18 mm | 23.14 mm |
Cash used (since last report) | 27.17 mm | 888.13 k | 4.93 mm | 160.73 mm | 143.71 mm | 156.99 mm |
Cash remaining | 145.11 mm | 171.39 mm | 167.35 mm | 11.55 mm | 28.57 mm | 15.29 mm |
Runway (months of cash) | 36.2 | 1309.2 | 230.2 | 0.5 | 1.3 | 0.7 |
Institutional ownership, Q3 2023
87.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 133 |
Opened positions | 22 |
Closed positions | 12 |
Increased positions | 42 |
Reduced positions | 38 |
13F shares | Current |
---|---|
Total value | 488.93 bn |
Total shares | 192.31 mm |
Total puts | 27.50 k |
Total calls | 24.80 k |
Total put/call ratio | 1.1 |
Largest owners | Shares | Value |
---|---|---|
ARCH Venture Fund IX | 44.04 mm | $0.00 |
Flagship Pioneering | 25.00 mm | $96.76 bn |
Flagship Ventures Fund V | 21.17 mm | $0.00 |
FMR | 15.90 mm | $61.53 bn |
Baillie Gifford & Co | 10.20 mm | $39.49 bn |
Canada Pension Plan Investment Board | 10.18 mm | $39.38 bn |
Vanguard | 9.17 mm | $35.48 bn |
BLK Blackrock | 7.99 mm | $30.94 bn |
T. Rowe Price | 7.03 mm | $27.41 bn |
STT State Street | 4.61 mm | $17.83 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
5 Apr 24 | Bishop Hans Edgar | Common Stock | Grant | Acquire A | No | No | 0 | 2,774 | 0.00 | 5,779,640 |
8 Mar 24 | Yang Patrick Y | Common Stock | Sell | Dispose S | No | No | 9.452 | 25,000 | 236.30 k | 149,250 |
7 Mar 24 | Williams Douglas E | Stock Option Common Stock | Grant | Acquire A | No | No | 9.58 | 301,875 | 2.89 mm | 301,875 |
7 Mar 24 | Williams Douglas E | RSU Common Stock | Grant | Acquire A | No | No | 0 | 67,083 | 0.00 | 67,083 |
7 Mar 24 | Steve Harr | Stock Option Common Stock | Grant | Acquire A | No | No | 9.58 | 900,000 | 8.62 mm | 900,000 |
7 Mar 24 | Steve Harr | RSU Common Stock | Grant | Acquire A | No | No | 0 | 200,000 | 0.00 | 200,000 |
News
10 Health Care Stocks Whale Activity In Today's Session
6 Mar 24
Tesla, Spirit Airlines, New York Community Bancorp And Other Big Stocks Moving Lower On Monday
4 Mar 24
Why Zscaler Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
1 Mar 24
JMP Securities Maintains Market Outperform on Sana Biotechnology, Raises Price Target to $15
1 Mar 24
Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday
1 Mar 24
Press releases
Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences
8 Apr 24
Flagship Pioneering Named to Fast Company's Annual List of the World's Most Innovative Companies of 2024
19 Mar 24
Sana Biotechnology Announces Pricing of Upsized Public Offering
8 Feb 24
Sana Biotechnology Announces Proposed Public Offering of Common Stock
7 Feb 24